自然環境より単離したThibacilus ferroxidansの鉄酸化酵素及び硫化水素酸化酵素活性

It has been reported that both iron oxidase and hydrogen sulfide: ferric ion oxidoreductase (SFORase) were involved in bacterial leaching of metal ions from sulfide ores, and the amount of Cu2+ solubilized from copper ore by iron-oxidizing bacterium differed from strain. The activities of iron oxidase SFORase of iron-oxidizing bacteria isolated from the natural environments were determined. Iron-oxidizing activity and SFORase activity of 200 strains ranged from 1.20-1.65γmol/mg/min and from 0.11-2.80 γmol/mg/min, respectively. The findings that a remarkable difference was observed in the levels of SFORase activity, but not in iron-oxidizing activity, suggest that SFORase, but not iron oxidase, is the enzyme that determines the bacterial leaching activity of this bacterium.鉄酸化酵素と硫化水素酸化酵素の両方が硫化鉱石からの金属イオンのバクテリアリーチングに関与していること、銅鉱石から溶出する銅イオンの量が鉄酸化細菌の菌株間で異なることが知られている。鉄酸化酵素及び硫化水素酸化酵素活性が自然環境から単離した鉄酸化細菌に対して決定された。200株の鉄酸化細菌の鉄酸化酵素及び硫化水素酸化酵素活性は、それぞれ、1.20-1.65γmol/mg/min及び0.11-2.80γmol/mg/minの範囲にあった。これら菌株間において、鉄酸化酵素ではなく硫化水素酸化酵素活性に大きく違いがあるという発見は、前者ではなく後者がこの細菌のバクテリアリーチング活性を決定する酵素であることを示唆している

The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

PURPOSE: The administration of aromatase inhibitors is associated with bone loss in postmenopausal women. We assessed changes in bone mineral density (BMD) from baseline to 60 months of treatment in patients receiving anastrozole as initial adjuvant therapy. METHODS: Postmenopausal women with hormone receptor-positive breast cancer receiving anastrozole as adjuvant therapy at our center since 2004 were enrolled in this study. BMD was assessed by dual-energy X-ray absorptiometry at baseline and after 6, 12, 24, 36, 48 and 60 months. Oral bisphosphonate (Bis) treatment was initiated when patients were diagnosed with osteoporosis having a T-score of −2.5 or lower. RESULTS: Fifty-five patients were enrolled in the study between 2004 and 2011, and the mean follow-up period was 53.6 months. Thirty-five patients were administered Bis (risedronate in 27 patients, alendronate in 8 patients). After 6 months of hormone therapy, BMD decreased by 0.5% from baseline at the lumbar spine (LS) and BMD decreased by 1.5% at the femoral neck (FN). However, BMD increased by 1.9% at the LS and BMD decreased by 1.5% at the FN for 60 months of treatment. In patients treated with upfront Bis (n = 19), 5.4% BMD increase from baseline was noted at the LS whereas in those without Bis (n = 21) BMD decreased by 4.3% from baseline within 24 months (P < 0.0001). Fractures were observed in 4 patients (7.3%), and 1 patient (1.8%) had a fragility fracture. CONCLUSIONS: Upfront treatment of Bis with anastrozole significantly increased BMD at the LS and an optimal use of Bis would not increase bone fractures. TRIAL REGISTRATION: UMIN000001757

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization.

PurposeTo compare the two-year outcome of half-time photodynamic therapy (htPDT) in chronic central serous chorioretinopathy (cCSC) with and without choroidal neovascularization (CNV).MethodsIn this retrospective study, we included 88 eyes of 88 patients with cCSC who underwent htPDT and were followed up for more than 24 months. Patients were divided into two groups with (21 eyes) or without (67 eyes) CNV before htPDT treatment. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and the presence of subretinal fluid (SRF) were evaluated at baseline and at 1, 3, 6, 12, and 24 months after PDT.ResultsA significant intergroup difference was noted in terms of age (P = 0.038). Significant improvements in the BCVA and SCT were found at all time points in eyes without CNV but only at 24 months in eyes with CNV. CRT was significantly reduced in both groups at all time points. No significant intergroup differences were noted in terms of BCVA, SCT and CRT at all time points. There were significant differences in the rate of recurrent and persistent SRF between groups (22.4% (without CNV) vs. 52.4% (with CNV), P = 0.013, and 26.9% (without CNV) vs. 57.1% (with CNV), P = 0.017, respectively). The presence of CNV was significantly associated with the recurrence and persistence of SRF after initial PDT (P = 0.007 and 0.028, respectively). Logistic regression analyses showed that the baseline BCVA, and not the presence of CNV, was significantly associated with BCVA at 24 months after initial PDT (P ConclusionsA htPDT for cCSC was less effective in eyes with CNV than in those without CNV regarding the recurrence and persistence of SRF. Additional treatment might be required in eyes with CNV during 24-month follow-up periods